Printer Friendly

Hello Alvin Partners with epay to Bring Healthcare Network to Retailers.

M2 PHARMA-May 24, 2017-Hello Alvin Partners with epay to Bring Healthcare Network to Retailers

(C)2017 M2 COMMUNICATIONS

- US-based mobile healthcare network Hello Alvin is partnering with epay, a Division of product processor and distributor Euronet Worldwide, Inc. (NASDAQ: EEFT), the company said.

The partnership brings the Hello Alvin secure, HIPAA-compliant suite of mobile healthcare tools to select epay retail partners, beginning with over 1,200 truck stops and travel centres in May.

This will be followed by Love's Travel Stops and Country Stores in June, will then expand to thousands of distribution points throughout epay's extensive distribution network.

Through its point-of-sale terminals, web-based POS solution, integrated POS systems and digital channel retailers, epay distributes a supply of prepaid products from many prepaid brands to retailers of all sizes.

The Hello Alvin healthcare product will be sold to consumers as prepaid codes, priced at USD 100 annually and merchandised alongside other popular prepaid products which epay distributes via its retail distribution network.

This annual subscription price includes unlimited Hello Alvin Nurse Line and Email-a-Doctor services and covers the entire family.

According to Hello Alvin, this first-time in retail offering also provides direct-to-consumer connectivity to the Teladoc physician telehealth network, allowing convenient and bilingual access to care for a wide range of non-emergent conditions ranging from the common cold to acute respiratory infections and the flu.

The cost to the patient is a USD 45 co-pay, significantly less than the cost of treating these conditions in an urgent care or emergency room setting.

Hello Alvin CEO and co-founder Joey Truscelli is no stranger to the healthcare technology industry, credited with developing one of the largest healthcare transaction clearinghouses in the United States ENS Health, now part of United Healthcare/Optum.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:May 24, 2017
Words:300
Previous Article:National Disease Research Interchange Adds Three New Directors to Board.
Next Article:Circulogene Adds Three Tests Supporting Personalised Treatment for Lung Cancer Patients.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters